Douglas A. Schober

3.3k total citations
55 papers, 2.7k citations indexed

About

Douglas A. Schober is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Douglas A. Schober has authored 55 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Cellular and Molecular Neuroscience, 45 papers in Molecular Biology and 6 papers in Reproductive Medicine. Recurrent topics in Douglas A. Schober's work include Receptor Mechanisms and Signaling (39 papers), Neuropeptides and Animal Physiology (35 papers) and Neuroscience and Neuropharmacology Research (10 papers). Douglas A. Schober is often cited by papers focused on Receptor Mechanisms and Signaling (39 papers), Neuropeptides and Animal Physiology (35 papers) and Neuroscience and Neuropharmacology Research (10 papers). Douglas A. Schober collaborates with scholars based in United States, Sweden and Australia. Douglas A. Schober's co-authors include Donald R. Gehlert, Susan L. Gackenheimer, Tammy J. Sajdyk, Robert A. Gadski, Magnus Berglund, Ingrid Lundell, Dan Larhammar, Michael A. Statnick, Lisa S. Beavers and Anantha Shekhar and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Brain Research.

In The Last Decade

Douglas A. Schober

55 papers receiving 2.7k citations

Peers

Countries citing papers authored by Douglas A. Schober

Since Specialization

Citations

This map shows the geographic impact of Douglas A. Schober's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas A. Schober with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas A. Schober more than expected).

Fields of papers citing papers by Douglas A. Schober

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas A. Schober. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas A. Schober. The network helps show where Douglas A. Schober may publish in the future.

Co-authorship network of co-authors of Douglas A. Schober

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas A. Schober. A scholar is included among the top collaborators of Douglas A. Schober based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas A. Schober. Douglas A. Schober is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography 2018 ·Journal of Pharmacology and Experimental Therapeutics ·Adrian J. Mogg, Thomas E. Eessalu, Megan Johnson, Rebecca A. Wright, Helen Sanger, (unknown), Michael Crabtree, (unknown), (unknown), Douglas A. Schober, Donald R. Gehlert, Cynthia D. Jesudason, Paul Goldsmith, Michael P. Johnson, Christian C. Felder, Vanessa Barth, Lisa M. Broad	8
2	Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain 2017 ·Journal of Pharmacology and Experimental Therapeutics ·Christian C. Felder, Douglas A. Schober, Yuan Tu, (unknown), (unknown), Marla L. Watt, (unknown), Eric S. Nisenbaum, Chuanxi Xiang, Beverly A. Heinz, Lourdes Prieto, David L. McKinzie, James A. Monn	5
3	LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy 2014 ·Frontiers in Neuroscience ·Thomas Fitch, Mark J. Benvenga, Cynthia D. Jesudason, (unknown), (unknown), (unknown), Douglas A. Schober, Linda M. Rorick‐Kehn	29
4	M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Jeffrey M. Witkin, C. Overshiner, (unknown), John T. Catlow, Graham N. Wishart, Douglas A. Schober, B.A. Heinz, Alexander Nikolayev, Vladimir Tolstikov, Wesley H. Anderson, Richard E. Higgs, Ming‐Shang Kuo, Christian C. Felder	88
5	Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Marla L. Watt, Douglas A. Schober, Stephen A. Hitchcock, Bin Liu, (unknown), David L. McKinzie, Christian C. Felder	30
6	The Use of Bioluminescence Resonance Energy Transfer 2 to Study Neuropeptide Y Receptor Agonist-Induced β-Arrestin 2 Interaction 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Magnus Berglund, Douglas A. Schober, Michael A. Statnick, Patricia McDonald, Donald R. Gehlert	63
7	Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala 2002 ·Pharmacology Biochemistry and Behavior ·Tammy J. Sajdyk, Douglas A. Schober, David L. Smiley, Donald R. Gehlert	104
8	Cloning and characterization of Rhesus monkey neuropeptide Y receptor subtypes 2001 ·Peptides ·Donald R. Gehlert, (unknown), Carolyn George, Yi Wang, Douglas A. Schober, Susan L. Gackenheimer, (unknown), Lisa S. Beavers, Robert A. Gadski, Melvyn Baez	12
9	Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists 1999 ·Bioorganic & Medicinal Chemistry Letters ·Hamideh Zarrinmayeh, Dennis M. Zimmerman, Buddy E. Cantrell, Douglas A. Schober, (unknown), Susan L. Gackenheimer, Paul L. Ornstein, Philip A. Hipskind, Thomas C. Britton, Donald R. Gehlert	82
10	Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: Optimization of the C-2 side chain 1999 ·Bioorganic & Medicinal Chemistry Letters ·Thomas C. Britton, (unknown), (unknown), Dennis M. Zimmerman, Hamideh Zarrinmayeh, Douglas A. Schober, Donald R. Gehlert, Robert F. Bruns	8
11	Characterization of the neuropeptide Y5 receptor in the human hypothalamus: a lack of correlation between Y5 mRNA levels and binding sites 1998 ·Brain Research ·Michael A. Statnick, Douglas A. Schober, Susan L. Gackenheimer, D. Brooke Johnson, Lisa S. Beavers, Nancy G. Mayne, J. Paul Burnett, Robert A. Gadski, Donald R. Gehlert	34
12	Increased expression of peripheral benzodiazepine receptors in the facial nucleus following motor neuron axotomy 1997 ·Neurochemistry International ·Donald R. Gehlert, Diane Stephenson, Douglas A. Schober, Karen Rash, James A. Clemens	33
13	[ 125 I]Leu 31 , Pro 34 -PYY is a High Affinity Radioligand for Rat PP1/Y4 and Y1 Receptors: Evidence for Heterogeneity in Pancreatic Polypeptide Receptors 1997 ·Peptides ·Donald R. Gehlert, Douglas A. Schober, Susan L. Gackenheimer, Lisa S. Beavers, Robert A. Gadski, Ingrid Lundell, Dan Larhammar	56
14	Pharmacological characterization of neuropeptide Y-(2–36) binding to neuropeptide Y Y1 and Y2 receptors 1996 ·European Journal of Pharmacology ·Douglas A. Schober, Susan L. Gackenheimer, Donald R. Gehlert	9
15	The neuropeptide Y Y1 receptor selective radioligand, [125I][Leu31,Pro34]peptide YY, is also a high affinity radioligand for human pancreatic polypeptide 1 receptors 1996 ·European Journal of Pharmacology ·Donald R. Gehlert, Susan L. Gackenheimer, Douglas A. Schober, Lisa S. Beavers, Robert A. Gadski, J. Paul Burnett, Nancy G. Mayne, Ingrid Lundell, Dan Larhammar	22
16	Cloning of a Human Receptor of the NPY Receptor Family with High Affinity for Pancreatic Polypeptide and Peptide YY 1995 ·Journal of Biological Chemistry ·Ingrid Lundell, Anders Blomqvist, Magnus Berglund, Douglas A. Schober, D. Brooke Johnson, Michael A. Statnick, Robert A. Gadski, Donald R. Gehlert, Dan Larhammar	281
17	Comparison of (R)‐[³H] Tomoxetine and (R/S)‐[³H] Nisoxetine Binding in Rat Brain 1995 ·Journal of Neurochemistry ·Donald R. Gehlert, Douglas A. Schober, Susan L. Gackenheimer	43
18	(R)-thionisoxetine, a potent and selective inhibitor of central and peripheral norepinephrine uptake 1995 ·Life Sciences ·Donald R. Gehlert, Susan K. Hemrick-Luecke, Douglas A. Schober, Joseph H. Krushinski, J. Jeffry Howbert, David W. Robertson, David T. Wong, Ray W. Fuller	17
19	Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain 1995 ·Neurochemistry International ·Donald R. Gehlert, Douglas A. Schober, Susan K. Hemrick-Luecke, Joseph H. Krushinski, J. Jeffry Howbert, David W. Robertson, Ray W. Fuller, Dawn M. Wong	32
20	Angiotensin II receptor subtypes in rat brain: dithiothreitol inhibits ligand binding to All-1 and enhances binding to All-2 1991 ·Brain Research ·Donald R. Gehlert, Susan L. Gackenheimer, Douglas A. Schober	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact